Alphabet's (GOOG, GOOGL) drug startup Isomorphic Labs is in early talks to raise new funds at a valuation of $40 billion to $50 billion, Bloomberg reported Thursday, citing unnamed people familiar with the matter.
The company, spun off from DeepMind, seeks to reduce the time to develop new drugs, the report said. It has already formed partnerships with Eli Lilly (LLY) and Novartis (NVS), the report added.
Isomorphic Labs did not immediately reply to MT Newswires' request for comment.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)